Dr. Baghbaderani is the global head of Process Development, Emerging Technologies at Lonza. He has over 15 years of experience in stem cells engineering, bioprocessing, and cell and gene therapy (C>) field. Dr. Baghbaderani holds a PhD degree in Biomedical Engineering from the University of Calgary (Calgary, Canada), where he developed bioreactor protocols for large-scale expansion of human neural stem cells for clinical applications. He completed nearly three years of postdoctoral program including a two-year postdoctoral fellowship at the National Institutes of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS). His postdoctoral research at the NIH focused on generation of human induced pluripotent stem cells, bioprocessing of both human embryonic stem cells and human iPSCs and controlled differentiation into neuronal lineage. Since joining Lonza in 2011, he has been working on developing new technologies and manufacturing processes around human pluripotent stem cells. Dr. Baghbaderani then led the cell therapy development department (including process development and bioassay services), focusing on the development of cGMP compliant processes and cell characterization assays for different cell therapy applications. As the global head of process development, Dr. Baghbaderani is currently leading the development activities for viral vector and C> applications across Lonza network.
Maria Agustina Duguine is a professional chemist, Italo-Argentine nationality, creator of a company dedicated to providing solutions for the industry. Formed in large multinationals (Bayer, Novartis), she has developed a system of GMP solutions with an exclusive and different treatment for each company-client, in order to facilitate the development of products and their export to the whole world. Today, the company has highly trained professionals in different areas, strategically located at three sites (Argentina, United States and Italy).
Dawn M. Ecker, M.S., Consultant and bioTRAK® Database Manager with BioProcess Technology Consultants, has over 25 years of experience in the biotechnology industry, ranging from from drug discovery, in vitro and in vivo screening, in vivo model development, pharmacokinetics, the manufacturing and purification of recombinant products and biopolymers and is highly skilled in secondary research required for biopharmaceutical market related analyses. At BioProcess Technology Consultants, she is responsible for managing the bioTRAK® database team and maintaining the company’s database for biopharmaceutical products, manufacturing capacity, and related topics, as well as for developing client-specific biopharmaceutical market-related analyses. Before joining BioProcess Technology Consultants, Ms. Ecker was a Research Fellow at the University of Massachusetts, Amherst where she managed the University’s Core Sequencing Facility, providing contract sequencing and real-time PCR services to the University community and several industrial clients. She also oversaw the day-to-day operations of the population genetics research laboratory and aided in the incorporation of high-throughput screening methods and equipment which enabled expedited research activities. Ms. Ecker holds a B.S. in Microbiology/Biotechnology from Quinnipiac University and an M.S. in Biology from Worcester Polytechnic Institute.
I’m a lead of international division specialising in international trade and competition, with a strong background in economics and commerce. Throughout most of my career, I have been looking to expand into global markets. I have extensive experience in the formulation and execution of business development and expansion strategies, and I’ve seen great success in introducing products into emerging markets. In addition, I’m also familiar with global trade facilitation, supply chain and logistics management, and regulatory through my various roles.
Craig Johnston is Industry Director at (CMAC) Continuous Manufacturing and Advanced Crystallisation. Established in 2011, CMAC is a world-class international centre for manufacturing research and training. Its vision is to lead the world in crystallisation and the adoption of continuous manufacturing. Working in partnership with industry it is transforming medicines manufacture. Craig works with Tier 1 industry members (GSK, AZ, Novartis, Bayer, Pfizer, Takeda, Eli Lilly, Roche and Pfizer) and a range of technology companies. Craig is a Fellow of the Institute of Chemical Engineers and has a MBA. His previous industrial career spanned 22 years, working for ICI, Zeneca, Avecia and Fujifilm. Responsibilities included plant management, new product introduction, process improvement, capital expenditure and process technology leadership. He was a Board Director with Britest. He is co-founder of sustainable protein business 3f Bio Ltd.
Director of Prestige BioPharam from Singapore. Michael has been working in the bio industry over two decades and professional antibody drug commercial developer and manufacturer.
Eric Langer has over 25 years experience in biotechnology and life sciences international marketing, management, market assessment, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. . He is an experienced biotechnology strategist, marketing practitioner, publisher, and researcher. He has published, edited and authored numerous books, reports, and major studies on topics including: Advances in Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, Biopharmaceuticals in the US Market, cell culture reports, media, sera, tissue engineering, stem cells, diagnostic products, blood products, genetics, DNA/PCR purification, blood components, and many others. He lectures extensively on pricing and channel management topics, and teaches at Johns Hopkins University and American University: Biotechnology Marketing, Marketing Management, Services Marketing, Advertising Strategy, and Bioscience Communication. He has developed numerous courses, classes and seminar programs, including Marketing in a Regulated Environment, Marketing Technical Products, and TechniManagement.™ In 1989 he co-founded BioPlan Associates, Inc. a biotechnology and life sciences marketing company that provides information, market research, pricing, and market analysis to biotechnology and healthcare organizations. He has launched and managed marketing programs for product lines ranging from $500k to $500 million. His company works with both large and small clients at commercial biotechs, non-profit organizations, and governments in assessing and evaluating markets, and marketing strategies and tactics.
Sander Leeuwenburgh studied Materials Science & Engineering at Delft University of Technology and graduated at the Laboratory of Inorganic Chemistry in 2001 (cum laude). In November 2006 he obtained his PhD degree (cum laude). Thereafter, he continued his scientific career as a postdoc until March 2008, when he was awarded a Young Investigator Award (VENI) by the Dutch Technology Foundation STW and was appointed as assistant professor at the Department of Biomaterials. In the framework of his VENI fellowship, he was visiting scholar at the Department of Biomaterials at Kyoto University Medical Hospital (Kyoto, Japan) from August 2009 until January 2010. In June 2015 he was appointed as associate professor after obtaining a prestigious VIDI award that enabled him to start his research group on nanostructured biomaterials. Since June 2016 he is Principal Investigator at the Radboud University Medical Center. In April 2018 he was appointed as full professor Regenerative Biomaterials at Radboudumc. He published more than 125 peer-reviewed papers and has an h-index of 29 (Web of Science) or 37 (Google Scholar).
Roxy Liu is Business Development Manager for Sinovac Biotech Co., Ltd. – a China-based biopharmaceutical Company that focuses on the R&D, manufacturing and commercialization of vaccines.
Her main mission in Sinovac is to establish long-time partnership with the distributors/vaccine manufacturers outside China. She hold a M. Sc. degree in Biochemistry.
André Markmann received his Ph.D. in Biochemistry in 2001, and started thereafter his career in the pharmaceutical industry. He worked for global leading companies like Aventis and DSM, and is active for Biotechpharma as Vice President Business Development since September 2014.
Mr. Meek received his BS in Chemical Engineering from North Carolina State University, with a concentration in biochemistry.He has over 13 years’ experience in
business development for preclinical research proof of concept services including in vivo and in vitro efficacy models to stable cell line development. Mr. Meek has forged numerous collaborations with global cGMP service providers and CMC consultants facilitating the production of multiple new molecules that have resulted in positive clinical outcomes and significant financial milestones.He led Business Development and Marketing for Aragen
Bioscience.Under Mr. Meek’s leadership in business development, Aragen’s sales grew 15 fold resulting in the acquisition of the company by GVK BIO, one of the largest contract research organizations in Asia.
John Milne PhD is the Training Director at the National Institute for Bioprocessing Research and Training, Dublin, Ireland., with responsibility for the development
Killian O’Driscoll is the Director of Projects at the National Institute for Bioprocessing Research and Training (NIBRT). Killian is a Genetics Graduate from Trinity College Dublin with an MSc in the Management of Innovation from the University of London. He also is an Associate Lecturer in Project Management at Dublin Business School. Prior to joining NIBRT, Killian worked with Microsoft European Operations Centre as Senior Global Project Manager and with Ericsson Competence Development Centre in the area of technology education and development. Killian working closely with all stakeholders in the biopharmaceutical industry has been involved in the successful establishment of NIBRT which has numerous international accolades including ISPE Facility of The Year, Bioprocess International Manufacturing Collaboration of the Decade and NIBRT is now recognized as a global leader in biopharma research and training.
Jos Olijve graduated at University Groningen-Netherlands in 1983. From 1983 to 1986, he worked as a Researcher in the Department of Molecular Genetics at the same University, investigating the area of isolation and characterization of proteins involved in the Transformation of Bacillus subtilis with chromosomal DNA. In 1986, he joined FujiFim Manufacturing Europe B.V as Senior Engineer and Project Leader and was in charge of the application development of photographic gelatins and of the characterization and the development of medical recombinant gelatin products. He joined Rousselot, a Darling Ingredients Company in 2012 where he is responsible for the development of new gelatin products and new gelatin based applications. Jos Olijve has published 15 patent applications and author/co-author of 10 scientific papers.
Amy Peck is the founder & CEO of EndeavorVR, a leading global VR/AR strategy & consulting firm. Amy speaks regularly on Enterprise VR/AR and has long been an evangelist for this technology. She holds several advisory board roles, is Co-chair of the VRARA Enterprise Committee and is an active mentor and member of several organizations including Women in Tech, Women in AR/VR and Sheryl Sandberg's Lean In Circles.
Amy's passion for virtual reality began at Leap Motion where she launched the Enterprise division working with clients across every major vertical including healthcare, entertainment, retail, hospitality, education and government. She helped these clients adopt VR & AR for both internal and customer-facing initiatives, often pairing them with talented developers and platform partners to bring these solutions to fruition.
It became clear that there was a need to help foster VR/AR development in the commercial arena and more importantly, shepherd these critical early wins. EndeavorVR was conceived for this very purpose.
Her own personal mission is to see VR/AR fundamentally improve every aspect of our lives
Philip joined Cobra in 2004 and is currently Sales and Marketing Director responsible for commercial sales activities within Europe and Asia and also overseeing the global marketing for Cobra with its three sites based in the UK and Sweden. Before Cobra, Philip had over 10 years of experience in various sales and marketing positions for diagnostics, large pharma and FMCG companies working both in Europe and Asia. Philip holds a BSc in Biology and French with a CIM qualification, having studied both in the UK and France
Dr. Ruotsalainen is a Senior R&D scientist at Admescope developing different analytical platforms for biopharmaceuticals. He has a broad background in bioanalytical development in clinical diagnostics industry.
Giorgio is part of the Business Unit, with responsibility of coordinating Business Development and Post sales activities
He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager; in this role he was an active member of the team in charge of building up the manufacturing plant, including mechanical installation of all the equipments, completion of commissioning and qualification of the lines, start up of production.
In 2014 he moved to Business Development to support the strategic growth of the Company.
Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth.
Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia
Dr. Marinella Sandros currently is the business development manager for life Sciences and SPRi product manager at HORIBA Scientific. She also currently holds an adjunct assistant professor position in the department of Nanoscience at the University of North Carolina at Greensboro since August 2015. Previously, she held a full time assistant professor position in the nanoscience department from 2010-2015. Her doctoral training was in bioinorganic chemistry from Wayne State University followed by her postdoctoral fellowship in biomedical engineering at McGill University. Dr. Sandros has extensive expertise in synthesizing and characterizing various types of nanomaterials to enhance their biointerfacing properties using different methods of coatings for biological applications. Furthermore, she has over 12 yrs experience in developing novel fluorescent, Raman and Surface Plasmon Resonance imaging (SPRi)-based biosensors through the integration of nanomaterials with biological interfaces. Finally, Dr. Sandros has authored numerous high impact journals demonstrating her strong expertise in developing, characterizing and applying nanomaterials.
Kevin Sharp is a Business Development Lead within the Global Business Development Center of Samsung Biologics. Mr. Sharp leads the establishment of development, clinical and commercial manufacturing partnerships.
Prior to joining Samsung Biologics, Mr. Sharp held various commercial and business development positions in pharmaceutical companies in the U.S.
Mr. Sharp began his career in the pharmaceutical industry with GlaxoSmithKline, serving in various procurement roles supporting their biologics, pharmaceutical and consumer healthcare businesses. He then worked in a Business Development role managing the sale of GSK’s capacity as a Contract Manufacturer. Transitioning to Contract Pharmacal Corp. as a Business Development Director, Mr. Sharp then managed global pharmaceutical CDMO activities.
Paul Thorning is a co-founder and Chief Executive Officer of CrystecPharma. He has over 25 years’ experience in the chemical and pharmaceutical industries in manufacturing, research, marketing, consultancy and senior executive roles. Paul was a former licensing director for AstraZeneca (member of Crestor acquisition team). Away from the pharmaceutical industry, Paul spent three years in Tanzania, Africa, where he was a programme director responsible for a team running hospitals, health programmes and community services for 140,000 Congolese refugees. Paul was subsequently appointed as Director of the Institute of Pharmaceutical Innovation at the University of Bradford, where he was actively involved in innovation in pharmaceutical sciences including the establishment of 3 innovation-based companies. Paul is a Non-Executive Director of Medilink North, and was appointed as the UK’s Focal Point for Health and Innovation with China. Paul speaks English, French, Italian and Swahili and intermediate Mandarin, holds an MBA and professional membership of the Institute of Marketing, and is a Fellow of the Institution of Mechanical Engineers
Marit van der Heijden holds a Master’s degree from the RSM Erasmus University in Rotterdam. She started her career in 2008 at SABIC, being (co)responsible for the introduction of certified bio based polymers, coordinating Life Cycle assessments, and working in the pricing team. In 2014, she joined Anova Seafood as CSR and Marketing Manager, being responsible for marketing unique propositions to European retail customers. In April 2018, she joined Rousselot as Marketing Manager. In this role, she is responsible for the global marketing activities for the Rousselot gelatin products.
Dr. Hosia is a Senior R&D scientist at Admescope developing LC-MS based analysis for biopharmaceuticals. He has a long history in bioanalytic and LC-MS in both, academia and private sector.
Samet Yildirim received a BSc in Biology and an MSc in Biophysics from Ankara University and an MBS degree in bioprocessing and business of bioscience from Keck Graduate Institute of California. From 2008 to 2013 he held various positions within responsibilities for research, product innovation and business development in various life science companies. In 2013 he joined Boehringer Ingelheim in Fremont, CA and involved with the development of continuous process platform. Currently he is leading a global innovation portfolio for the Next Generation Manufacturing of biopharmaceuticals in Boehringer Ingelheim Biopharma Business Unit